Efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II study

BACKGROUND: Recent preclinical and phase I studies have reported that rebamipide decreased the severity of chemoradiotherapy-induced oral mucositis in patients with oral cancer. This placebo-controlled randomized phase II study assessed the clinical benefit of rebamipide in reducing the incidence of...

Descripción completa

Detalles Bibliográficos
Autores principales: Yokota, T., Ogawa, T., Takahashi, S., Okami, K., Fujii, T., Tanaka, K., Iwae, S., Ota, I., Ueda, T., Monden, N., Matsuura, K., Kojima, H., Ueda, S., Sasaki, K., Fujimoto, Y., Hasegawa, Y., Beppu, T., Nishimori, H., Hirano, S., Naka, Y., Matsushima, Y., Fujii, M., Tahara, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5420134/
https://www.ncbi.nlm.nih.gov/pubmed/28476132
http://dx.doi.org/10.1186/s12885-017-3295-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5420134/
https://www.ncbi.nlm.nih.gov/pubmed/28476132
http://dx.doi.org/10.1186/s12885-017-3295-4

Ejemplares similares